GCILungLife AI's LungLB cancer test achieves milestone with peer-reviewed publication
One of the beauties of investing in the life sciences sector is the strong IPR, attractive profit margins, and high barriers to entry.
Equally, however, adoption of breakthrough technologies in the real world can take time - especially when key opinion leaders, industry bodies, doctors, nurses, health insurers and patients need to be educated about innovative new products such as 's cutting edge, early-stage lung cancer blood test LungLB.
One of the best ways of accelerating this commercialisation process is having the new solution peer-reviewed in an influential and respected journal.
Similarly, () said today that LungLB's analytical validation had been accepted for publication in BMC Pulmonary Medicine, which is a globally recognised peer-reviewed medical journal covering all aspects of the prevention, diagnosis and management of pulmonary and associated disorders.
In turn, this not only builds trust and confidence across the scientific and medical communities for LungLB, but it also adds to the growing body of evidence, including clinical validity and health economics data - with the near-term objective of obtaining Medicare coverage, offering the diagnostic to patients and increasing the likelihood of the test being adopted throughout the US.
Here the journal's findings confirmed once again that LungLB worked consistently well, no matter which lab technician was running it or which batch of materials was used, demonstrating that the test is reliable and well-designed.
CEO Paul Pagano commenting: "Having the results of our study peer-reviewed and published is a significant milestone, validating the scientific rigour of our research. This achievement is a key part of our commercialisation strategy to build a bank of evidence of the efficacy and utility of our testing. It underscores both the credibility of our LungLB® test and provides greater confidence in its use, and importantly, by raising awareness about the test it supports our commitment to expanding access for those who need it most."
In terms of the numbers, house broker Investec has a 171p/share target price, and is forecasting revenues to climb from $0.1m in FY24 to $0.5m and $1.2m over the next two years.
Follow News & Updates from LungLife AI:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.